>>> US Research Calls II

Research Calls II
  • Upgrades:
    • Brixmor Property (BRX) upgraded to Outperform from In-line at Evercore ISI
    • Equifax (EFX) downgraded to Hold from Buy at Argus
    • Genmab (GMAB) upgraded to Neutral from Underperform at Exane BNP Paribas
    • Peloton (PTON) upgraded to Buy from Hold at Argus; tgt $15
    • RTX (RTX) upgraded to Buy from Hold at Argus
    • Southwest Air (LUV) upgraded to Buy from Hold at Argus; tgt $35
  • Downgrades:
    • First National (FXNC) downgraded to Market Perform from Outperform at Hovde Group; tgt $28.50
    • Q32 Bio (QTTB) downgraded to Neutral from Overweight at Piper Sandler; tgt lowered to $4
    • Q32 Bio (QTTB) downgraded to Market Perform from Outperform at BMO Capital Markets; tgt lowered to $3
    • REGENXBIO (RGNX) downgraded to Neutral from Buy at Goldman; tgt lowered to $14
  • Others:
    • Alkermes Plc (ALKS) initiated with a Buy at Deutsche Bank; tgt $40
    • Avadel Pharmaceuticals (AVDL) initiated with a Buy at Deutsche Bank; tgt $12
    • Axsome Therapeutics (AXSM) initiated with a Buy at Deutsche Bank; tgt $176
    • Gaia (GAIA) initiated with a Buy at ROTH MKM; tgt $10
    • Harmony Biosciences (HRMY) initiated with a Buy at Deutsche Bank; tgt $55
    • Marker Therapeutics (MRKR) initiated with a Buy at Brookline
    • Neurocrine Biosciences (NBIX) initiated with a Hold at Deutsche Bank; tgt $138
    • Xenon Pharmaceuticals (XENE) initiated with a Buy at Deutsche Bank; tgt $67